0001127602-22-014951.txt : 20220518 0001127602-22-014951.hdr.sgml : 20220518 20220518162646 ACCESSION NUMBER: 0001127602-22-014951 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220516 FILED AS OF DATE: 20220518 DATE AS OF CHANGE: 20220518 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Simon, Christopher CENTRAL INDEX KEY: 0001674993 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14041 FILM NUMBER: 22939482 BUSINESS ADDRESS: STREET 1: HAEMONETICS CORPORATION STREET 2: 400 WOOD ROAD CITY: BRAINTREE STATE: MA ZIP: 02184 BUSINESS PHONE: 781-356-7100 MAIL ADDRESS: STREET 1: HAEMONETICS CORPORATION STREET 2: 400 WOOD ROAD CITY: BRAINTREE STATE: MA ZIP: 02184 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HAEMONETICS CORP CENTRAL INDEX KEY: 0000313143 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042882273 STATE OF INCORPORATION: MA FISCAL YEAR END: 0402 BUSINESS ADDRESS: STREET 1: 125 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 7818487100 MAIL ADDRESS: STREET 1: 125 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02110 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2022-05-16 0000313143 HAEMONETICS CORP HAE 0001674993 Simon, Christopher 125 SUMMER STREET BOSTON MA 02110 1 1 President & CEO Common Stock 2022-05-16 4 S 0 832 56.10 D 191327 D Common Stock 2022-05-16 4 A 0 26041 A 217368 D Non-qualified Stock Option (Right to Buy) 57.60 2022-05-16 4 A 0 60891 0 A 2029-05-16 Common Stock 60891 60891 D Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. This number includes unvested RSUs previously reported as well as 353 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 29, 2022. The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. /s/ Thomas V. Powers, attorney-in-fact for Mr. Simon 2022-05-18